Feyerabend, Susan

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 736

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., et al. (2020) · Targeted Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 86

Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients

Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer

Immunotherapy and Immune Responsesvaccines and immunoinformatics approaches

Cited by 70

Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: updated analysis of KEYNOTE-199

Antonarakis, E. S., Goh, J. C., Gross-Goupil, M., Vaishampayan, U. N., Piulats, J. M., De Wit, R., Alanko, T., Fukasawa, S., Tabata, K., Feyerabend, S., et al. (2019) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 13